Stawicki Stanislaw P, Stoltzfus Jill C, Aggarwal Praveen, Bhoi Sanjeev, Bhatt Shashi, Kalra O P, Bhalla Ashish, Hoey Brian A, Galwankar Sagar C, Paladino Lorenzo, Papadimos Thomas J
Department of Research and Innovation, Research Institute, Bethlehem, Pennsylvania ; Department of Research and Innovation, OPUS 12 Foundation Global, Columbus, USA.
Department of Research and Innovation, Research Institute, Bethlehem, Pennsylvania ; Department of Research and Innovation, Research Institute, Bethlehem, Pennsylvania.
Int J Crit Illn Inj Sci. 2014 Jul;4(3):200-8. doi: 10.4103/2229-5151.141398.
Biomarker science brings great promise to clinical medicine. This is especially true in the era of technology miniaturization, rapid dissemination of knowledge, and point-of-care (POC) implementation of novel diagnostics. Despite this tremendous progress, the journey from a candidate biomarker to a scientifically validated biomarker continues to be an arduous one. In addition to substantial financial resources, biomarker research requires considerable expertise and a multidisciplinary approach. Investigational designs must also be taken into account, with the randomized controlled trial remaining the "gold standard". The authors present a condensed overview of biomarker science and associated investigational methods, followed by specific examples from clinical areas where biomarker development and/or implementation resulted in tangible enhancements in patient care. This manuscript also serves as a call to arms for the establishment of a truly global, well-coordinated infrastructure dedicated to biomarker research and development, with focus on delivery of the latest discoveries directly to the patient via point-of-care technology.
生物标志物科学给临床医学带来了巨大希望。在技术小型化、知识快速传播以及新型诊断技术的即时检验(POC)应用的时代,情况尤其如此。尽管取得了巨大进展,但从候选生物标志物到经过科学验证的生物标志物的历程仍然十分艰巨。除了大量资金资源外,生物标志物研究还需要相当多的专业知识和多学科方法。还必须考虑研究设计,随机对照试验仍然是“金标准”。作者简要概述了生物标志物科学及相关研究方法,随后列举了临床领域的具体实例,在这些领域中生物标志物的开发和/或应用切实改善了患者护理。本手稿还呼吁建立一个真正全球化、协调良好的基础设施,致力于生物标志物的研发,重点是通过即时检验技术将最新发现直接提供给患者。